Integrated clinical, histopathological, and molecular data analysis of 190 central nervous system germ cell tumors from the iGCT Consortium.
germ cell tumor
pathological diagnosis
prognosis, tumor marker
rare disease
Journal
Neuro-oncology
ISSN: 1523-5866
Titre abrégé: Neuro Oncol
Pays: England
ID NLM: 100887420
Informations de publication
Date de publication:
17 12 2019
17 12 2019
Historique:
pubmed:
20
8
2019
medline:
19
8
2020
entrez:
18
8
2019
Statut:
ppublish
Résumé
We integrated clinical, histopathological, and molecular data of central nervous system germ cell tumors to provide insights into their management. Data from the Intracranial Germ Cell Tumor Genome Analysis (iGCT) Consortium were reviewed. A total of 190 cases were classified as primary germ cell tumors (GCTs) based on central pathological reviews. All but one of the cases that were bifocal (neurohypophysis and pineal glands) and cases with multiple lesions including neurohypophysis or pineal gland were germinomas (34 of 35). Age was significantly higher in patients with germinoma than other histologies. Comparison between tumor marker and histopathological diagnoses showed that 18.2% of histopathologically diagnosed germinomas were marker positive and 6.1% of non-germinomatous GCTs were marker negative, suggesting a limitation in the utility of markers or histopathology alone using small specimens for diagnosis. Comparison between local and central histopathological diagnoses revealed a discordance of 12.7%. Discordance was significantly less frequent in biopsy cases, implying difficulty in detecting all histopathological components of heterogeneous GCTs. Germinomas at the typical sites (neurohypophysis or pineal gland) showed a better progression-free survival than those at atypical sites (P = 0.03). A molecular clinical association study revealed frequent mitogen-activated protein kinase (MAPK) pathway mutations in males (51.4% vs 14.3%, P = 0.007), and phosphatidylinositol-3 kinase/mammalian target of rapamycin (PI3K/mTOR) pathway mutations in basal ganglia cases (P = 0.004). Basal ganglia cases also had frequent chromosomal losses. Some chromosomal aberrations (2q, 8q gain, 5q, 9p/q, 13q, 15q loss) showed potential prognostic significance. The in-depth findings of this study regarding clinical and molecular heterogeneity will increase our understanding of the pathogenesis of this enigmatic tumor.
Sections du résumé
BACKGROUND
We integrated clinical, histopathological, and molecular data of central nervous system germ cell tumors to provide insights into their management.
METHODS
Data from the Intracranial Germ Cell Tumor Genome Analysis (iGCT) Consortium were reviewed. A total of 190 cases were classified as primary germ cell tumors (GCTs) based on central pathological reviews.
RESULTS
All but one of the cases that were bifocal (neurohypophysis and pineal glands) and cases with multiple lesions including neurohypophysis or pineal gland were germinomas (34 of 35). Age was significantly higher in patients with germinoma than other histologies. Comparison between tumor marker and histopathological diagnoses showed that 18.2% of histopathologically diagnosed germinomas were marker positive and 6.1% of non-germinomatous GCTs were marker negative, suggesting a limitation in the utility of markers or histopathology alone using small specimens for diagnosis. Comparison between local and central histopathological diagnoses revealed a discordance of 12.7%. Discordance was significantly less frequent in biopsy cases, implying difficulty in detecting all histopathological components of heterogeneous GCTs. Germinomas at the typical sites (neurohypophysis or pineal gland) showed a better progression-free survival than those at atypical sites (P = 0.03). A molecular clinical association study revealed frequent mitogen-activated protein kinase (MAPK) pathway mutations in males (51.4% vs 14.3%, P = 0.007), and phosphatidylinositol-3 kinase/mammalian target of rapamycin (PI3K/mTOR) pathway mutations in basal ganglia cases (P = 0.004). Basal ganglia cases also had frequent chromosomal losses. Some chromosomal aberrations (2q, 8q gain, 5q, 9p/q, 13q, 15q loss) showed potential prognostic significance.
CONCLUSIONS
The in-depth findings of this study regarding clinical and molecular heterogeneity will increase our understanding of the pathogenesis of this enigmatic tumor.
Identifiants
pubmed: 31420671
pii: 5550931
doi: 10.1093/neuonc/noz139
pmc: PMC6917411
doi:
Substances chimiques
Biomarkers, Tumor
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1565-1577Informations de copyright
© The Author(s) 2019. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Références
Neuro Oncol. 2013 Jun;15(6):788-96
pubmed: 23460321
Nat Rev Cancer. 2005 Mar;5(3):210-22
pubmed: 15738984
Eur J Cancer. 1998 Jan;34(1):104-10
pubmed: 9624246
Neuro Oncol. 2015 May;17(5):741-6
pubmed: 25422317
Neuro Oncol. 2004 Apr;6(2):127-33
pubmed: 15134627
J Neurosurg Pediatr. 2016 Nov;18(5):573-577
pubmed: 27391806
Acta Neuropathol. 2017 Mar;133(3):445-462
pubmed: 28078450
J Neurooncol. 2001 Sep;54(3):311-6
pubmed: 11767296
Neuroradiology. 1998 Aug;40(8):507-11
pubmed: 9763338
J Clin Oncol. 2015 Aug 1;33(22):2464-71
pubmed: 26101244
Int J Radiat Oncol Biol Phys. 2005 Jul 1;62(3):803-8
pubmed: 15936563
Neuro Oncol. 2017 Nov 29;19(12):1661-1672
pubmed: 29048505
Cancer. 2000 Jan 1;88(1):162-8
pubmed: 10618619
World Neurosurg. 2016 Nov;95:516-524.e1
pubmed: 27567571
J Neurooncol. 2015 Aug;124(1):23-32
pubmed: 25994796
J Neurooncol. 2009 Sep;94(3):351-8
pubmed: 19373436
J Neurosurg. 1997 Mar;86(3):446-55
pubmed: 9046301
Acta Neuropathol. 2016 Jun;131(6):889-901
pubmed: 26956871
Acta Neuropathol. 2014;127(6):911-25
pubmed: 24452629
Neuro Oncol. 2015 Oct;17 Suppl 4:iv1-iv62
pubmed: 26511214
Neuro Oncol. 2013 Jul;15(7):955-60
pubmed: 23640532
Lancet Oncol. 2015 Sep;16(9):e470-e477
pubmed: 26370356